Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry

International Journal of Cardiology

Volumn 170, Issue 3, 2014, Pages 413-418

  Ruff, Christian T ^a   Bhatt, Deepak L ^b   Steg, Ph Gabriel ^c   Gersh, Bernard J ^d   Alberts, Mark J ^e   Hoffman, Elaine B ^a   Ohman, E Magnus ^f   Eagle, Kim A ^g   Lip, Gregory Y H ^h   Goto, Shinya ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d MAYO CLINIC   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticoagulation; Atherosclerosis; Atrial fibrillation; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOKING; THROMBOSIS;

ANTICOAGULATION; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; DIABETES MELLITUS; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; STROKE; THROMBOSIS; TIME FACTORS;

EID: 84891001656     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.11.030     Document Type: Article

References (44)

1. V. Fuster, L.E. Ryden, and D.S. Cannom et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
2. D. Hu, and Y. Sun Epidemiology, risk factors for stroke, and management of atrial fibrillation in China J Am Coll Cardiol 52 2008 865 868
3. Y. Miyasaka, M.E. Barnes, and B.J. Gersh et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125
4. D. Fatkin, R.P. Kelly, and M.P. Feneley Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo J Am Coll Cardiol 23 1994 961 969
5. J.J. Hwang, F.N. Ko, and Y.H. Li et al. Clinical implications and factors related to left atrial spontaneous echo contrast in chronic nonvalvular atrial fibrillation Cardiology 85 1994 69 75
6. G.A. Pop, H.J. Meeder, and J.R. Roelandt et al. Transthoracic echo/Doppler in the identification of patients with chronic non-valvular atrial fibrillation at risk for thromboembolic events Eur Heart J 15 1994 1545 1551
7. D.S. Conway, L.A. Pearce, B.S. Chin, R.G. Hart, and G.Y. Lip Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors Circulation 106 2002 1962 1967
8. D.S. Conway, L.A. Pearce, B.S. Chin, R.G. Hart, and G.Y. Lip Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation Circulation 107 2003 3141 3145
9. K.M. Flegel, M.J. Shipley, and G. Rose Risk of stroke in non-rheumatic atrial fibrillation Lancet 1 1987 526 529
10. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
11. A.D. Krahn, J. Manfreda, R.B. Tate, F.A. Mathewson, and T.E. Cuddy The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study Am J Med 98 1995 476 484
12. J.P. Depta, and D.L. Bhatt Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes Thromb Haemost 104 2010 657 663
13. R. Nieuwlaat, A. Capucci, and A.J. Camm et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation Eur Heart J 26 2005 2422 2434
14. M. Nabauer, A. Gerth, and T. Limbourg et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management Europace 11 2009 423 434
15. P. Jabre, X. Jouven, and F. Adnet et al. Atrial fibrillation and death after myocardial infarction: a community study Circulation 123 2011 2094 2100
16. J. Schmitt, G. Duray, B.J. Gersh, and S.H. Hohnloser Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications Eur Heart J 30 2009 1038 1045
17. L.H. Rasmussen, T.B. Larsen, K.M. Due, A. Tjonneland, K. Overvad, and G.Y. Lip Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study J Thromb Haemost 9 2011 1301 1307
18. L.Y. Lin, C.H. Lee, and C.C. Yu et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation - a nationwide database analysis Atherosclerosis 217 2011 292 295
19. T.S. Tsang, B.J. Gersh, and C.P. Appleton et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women J Am Coll Cardiol 40 2002 1636 1644
20. T.S. Tsang, M.E. Barnes, and B.J. Gersh et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography J Am Coll Cardiol 42 2003 1199 1205
21. P.S. Douglas The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk J Am Coll Cardiol 42 2003 1206 1207
22. E.M. Ohman, D.L. Bhatt, and P.G. Steg et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events - study design Am Heart J 151 2006 [786.e1-786.10]
23. D.L. Bhatt, P.G. Steg, and E.M. Ohman et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 2006 180 189
24. P.G. Steg, D.L. Bhatt, and P.W. Wilson et al. One-year cardiovascular event rates in outpatients with atherothrombosis JAMA 297 2007 1197 1206
25. M.J. Alberts, D.L. Bhatt, and J.L. Mas et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry Eur Heart J 30 2009 2318 2326
26. D.L. Bhatt, K.A. Eagle, and E.M. Ohman et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis JAMA 304 2010 1350 1357
27. S. Goto, D.L. Bhatt, and J. Rother et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis Am Heart J 156 2008 855 863 [863.e2]
28. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
29. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
30. J. Heeringa, D.A. van der Kuip, and A. Hofman et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J 27 2006 949 953
31. T.J. Bungard, W.A. Ghali, and F.A. McAlister et al. The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation Can J Cardiol 19 2003 280 284
32. C.P. Gross, E.W. Vogel, and A.J. Dhond et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey Clin Ther 25 2003 1750 1764
33. M.J. Alberts, D.L. Bhatt, and S.C. Smith Jr. et al. Risk factors and outcomes for patients with vascular disease and serious bleeding events Heart 97 2011 1507 1512
34. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
35. S.R. Mehta, S. Yusuf, and R.J. Peters et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
36. S.C. Beinart, P. Kolm, and E. Veledar et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial J Am Coll Cardiol 46 2005 761 769
37. D.P. Faxon, J.W. Eikelboom, and P.B. Berger et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective Thromb Haemost 106 2011 572 584
38. J.P. Depta, C.P. Cannon, and G.C. Fonarow et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes Am J Cardiol 104 2009 1171 1178
39. ACTIVE Writing Group of the ACTIVE Investigators, S. Connolly, and J. Pogue et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
40. S.J. Connolly, J. Eikelboom, and C. Joyner et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
41. M.B. Rothberg, C. Celestin, L.D. Fiore, E. Lawler, and J.R. Cook Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit Ann Intern Med 143 2005 241 250
42. G.Y. Lip, and D.A. Lane Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 123 2010 785 789
43. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 5 2012 397 402
44. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, and A.J. Camm et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429